About Adaptive Biotechnologies
Adaptive Biotechnologies is a company based in Seattle (United States) founded in 2009 by Harlan Robins and Chad Robins.. Adaptive Biotechnologies has raised $419.15 million across 18 funding rounds from investors including Microsoft, Illumina and LabCorp. The company has 619 employees as of December 31, 2024. Adaptive Biotechnologies has completed 1 acquisition, including Sequenta. Adaptive Biotechnologies offers products and services including clonoSEQ, Adaptive Immunosequencing, and Pharma Services. Adaptive Biotechnologies operates in a competitive market with competitors including Moderna, Chimerix, HOOKIPA Pharma, Novavax and Generate Biomedicines, among others.
- Headquarter Seattle, United States
- Employees 619 as on 31 Dec, 2024
- Founders Harlan Robins, Chad Robins
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adaptive Biotechnologies Corporation
-
Annual Revenue
$178.96 M5.1as on Dec 31, 2024
-
Net Profit
$-159.49 M29.19as on Dec 31, 2024
-
EBITDA
$-134.08 M25.25as on Dec 31, 2024
-
Total Equity Funding
$419.15 M (USD)
in 18 rounds
-
Latest Funding Round
-
Investors
Microsoft
& 13 more
-
Employee Count
619
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adaptive Biotechnologies
Adaptive Biotechnologies is a publicly listed company on the NASDAQ with ticker symbol ADPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Adaptive Biotechnologies
Adaptive Biotechnologies offers a comprehensive portfolio of products and services, including clonoSEQ, Adaptive Immunosequencing, and Pharma Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
NGS-based tool for assessing minimal residual disease in trials.
Technology for mapping immune receptors in drug discovery.
Services supporting clinical diagnostics and therapeutic development.
Unlock access to complete
Unlock access to complete
Software Development Team
62 people
Senior Team
36 people
Leadership Team
35 people
Operations Team
17 people
Sales and Marketing
16 people
Product Management Team
14 people
Research Team
12 people
Human Resources and Administration
11 people
Unlock access to complete
Funding Insights of Adaptive Biotechnologies
Adaptive Biotechnologies has successfully raised a total of $419.15M across 18 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 18
- Last Round Last Round
-
First Round
First Round
(28 Dec 2009)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2018 | Amount | Series F - Adaptive Biotechnologies | Valuation |
investors |
|
| May, 2015 | Amount | Series F - Adaptive Biotechnologies | Valuation | Matrix | |
| Jan, 2015 | Amount | Series E - Adaptive Biotechnologies | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adaptive Biotechnologies
Adaptive Biotechnologies has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Microsoft, Illumina and LabCorp. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adaptive Biotechnologies
Adaptive Biotechnologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Sequenta. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Adaptive Biotechnologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adaptive Biotechnologies Comparisons
Competitors of Adaptive Biotechnologies
Adaptive Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Chimerix, HOOKIPA Pharma, Novavax and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adaptive Biotechnologies
Frequently Asked Questions about Adaptive Biotechnologies
When was Adaptive Biotechnologies founded?
Adaptive Biotechnologies was founded in 2009.
Where is Adaptive Biotechnologies located?
Adaptive Biotechnologies is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Who is the current CEO of Adaptive Biotechnologies?
Chad Robins is the current CEO of Adaptive Biotechnologies. They have also founded this company.
Is Adaptive Biotechnologies a funded company?
Adaptive Biotechnologies is a funded company, having raised a total of $419.15M across 18 funding rounds to date. The company's 1st funding round was a Series E of $94M, raised on Dec 28, 2009.
How many employees does Adaptive Biotechnologies have?
As of Dec 31, 2024, the latest employee count at Adaptive Biotechnologies is 619.
What is the annual revenue of Adaptive Biotechnologies?
Annual revenue of Adaptive Biotechnologies is $178.96M as on Dec 31, 2024.
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies was founded in 2009 in Seattle, United States. Operations focus on the biotechnology sector, with services centered on immune disease diagnostics and drug discovery. The immunoSEQ sequencing technology is utilized to characterize the immune system, supporting scientific research and clinical development. clonoSEQ is employed for monitoring minimal residual disease in blood-based cancers. Cell therapies, vaccines, and antibody molecules are developed for infectious diseases.
Who are the top competitors of Adaptive Biotechnologies?
Adaptive Biotechnologies's top competitors include Moderna, Generate Biomedicines and HOOKIPA Pharma.
What products or services does Adaptive Biotechnologies offer?
Adaptive Biotechnologies offers clonoSEQ, Adaptive Immunosequencing, and Pharma Services.
Is Adaptive Biotechnologies publicly traded?
Yes, Adaptive Biotechnologies is publicly traded on NASDAQ under the ticker symbol ADPT.
How many acquisitions has Adaptive Biotechnologies made?
Adaptive Biotechnologies has made 1 acquisition, including Sequenta.
Who are Adaptive Biotechnologies's investors?
What is Adaptive Biotechnologies's ticker symbol?
The ticker symbol of Adaptive Biotechnologies is ADPT on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.